Lowering cost of antibiotics via continuous reactive crystallization

The pharmaceutical industry traditionally uses batch manufacturing for medicine production. However, this approach has its drawbacks, including increased costs associated with starting up and shutting down production and inconsistent product quality. Due to the rising costs of drug development and the need for improved quality, the industry is now seeking ways to improve the efficiency of manufacturing existing medicines.

One promising solution is continuous manufacturing. By adopting this approach, pharmaceutical companies can increase efficiency, enhance product quality, and reduce the cost of medicine. Reactive crystallization is a complementary approach that can further benefit the pharmaceutical manufacturing process. It combines synthesis and crystallization into a single step, allowing for the direct transformation of starting materials into a pure solid product.

Continuous reactive crystallization of antibiotics has great potential to improve access to scarce drugs. By streamlining the production process, it can help ensure that life-saving antibiotics are more readily available to those who need them.